News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,349 Results
Type
Article (42560)
Company Profile (438)
Press Release (676350)
Multimedia
Podcasts (84)
Webinars (14)
Section
Business (208841)
Career Advice (2023)
Deals (36034)
Drug Delivery (104)
Drug Development (83650)
Employer Resources (173)
FDA (16484)
Job Trends (15120)
News (353045)
Policy (33128)
Tag
Academia (2645)
Accelerated approval (9)
Adcomms (26)
Allergies (95)
Alliances (51067)
ALS (107)
Alzheimer's disease (1465)
Antibody-drug conjugate (ADC) (166)
Approvals (16462)
Artificial intelligence (311)
Autoimmune disease (30)
Automation (18)
Bankruptcy (373)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (111)
Biotechnology (331)
Bladder cancer (93)
Brain cancer (32)
Breast cancer (360)
Cancer (2786)
Cardiovascular disease (215)
Career advice (1691)
Career pathing (30)
CAR-T (185)
CDC (28)
Cell therapy (501)
Cervical cancer (22)
Clinical research (68402)
Collaboration (1003)
Company closure (3)
Compensation (642)
Complete response letters (24)
COVID-19 (2674)
CRISPR (61)
C-suite (305)
Cystic fibrosis (114)
Data (2841)
Decentralized trials (2)
Denatured (29)
Depression (61)
Diabetes (310)
Diagnostics (6469)
Digital health (22)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (126)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (88619)
Editorial (44)
Employer branding (21)
Employer resources (148)
Events (117164)
Executive appointments (854)
FDA (18032)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (916)
Gene editing (136)
Generative AI (22)
Gene therapy (386)
GLP-1 (791)
Government (4561)
Grass and pollen (4)
Guidances (180)
Healthcare (19167)
Huntington's disease (30)
IgA nephropathy (38)
Immunology and inflammation (151)
Immuno-oncology (6)
Indications (37)
Infectious disease (2830)
Inflammatory bowel disease (154)
Inflation Reduction Act (12)
Influenza (57)
Intellectual property (115)
Interviews (312)
IPO (16857)
IRA (46)
Job creations (3706)
Job search strategy (1434)
Kidney cancer (13)
Labor market (49)
Layoffs (516)
Leadership (18)
Legal (7999)
Liver cancer (79)
Lung cancer (395)
Lymphoma (196)
Machine learning (9)
Management (58)
Manufacturing (369)
MASH (87)
Medical device (13576)
Medtech (13581)
Mergers & acquisitions (19843)
Metabolic disorders (810)
Multiple sclerosis (96)
NASH (19)
Neurodegenerative disease (124)
Neuropsychiatric disorders (37)
Neuroscience (2143)
NextGen: Class of 2025 (6759)
Non-profit (4556)
Now hiring (46)
Obesity (424)
Opinion (233)
Ovarian cancer (95)
Pain (106)
Pancreatic cancer (111)
Parkinson's disease (185)
Partnered (22)
Patents (283)
Patient recruitment (140)
Peanut (50)
People (58980)
Pharmaceutical (86)
Pharmacy benefit managers (21)
Phase I (21512)
Phase II (30193)
Phase III (22292)
Pipeline (1576)
Policy (193)
Postmarket research (2601)
Preclinical (9235)
Press Release (67)
Prostate cancer (134)
Psychedelics (38)
Radiopharmaceuticals (270)
Rare diseases (463)
Real estate (6021)
Recruiting (66)
Regulatory (22952)
Reports (50)
Research institute (2419)
Resumes & cover letters (352)
Rett syndrome (9)
RNA editing (9)
RSV (45)
Schizophrenia (88)
Series A (160)
Series B (106)
Service/supplier (11)
Sickle cell disease (63)
Special edition (21)
Spinal muscular atrophy (152)
Sponsored (32)
Startups (3771)
State (2)
Stomach cancer (14)
Supply chain (73)
Tariffs (55)
The Weekly (53)
Vaccines (764)
Venture capital (50)
Weight loss (266)
Women's health (45)
Worklife (17)
Date
Today (140)
Last 7 days (538)
Last 30 days (2623)
Last 365 days (32322)
2025 (15627)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27110)
2012 (29220)
2011 (29864)
2010 (27994)
Location
Africa (737)
Alabama (65)
Alaska (7)
Arizona (250)
Arkansas (14)
Asia (39542)
Australia (6567)
California (7289)
Canada (2269)
China (653)
Colorado (309)
Connecticut (323)
Delaware (183)
Europe (86491)
Florida (1077)
Georgia (240)
Idaho (58)
Illinois (632)
India (26)
Indiana (352)
Iowa (18)
Japan (213)
Kansas (111)
Kentucky (28)
Louisiana (14)
Maine (64)
Maryland (1014)
Massachusetts (5512)
Michigan (242)
Minnesota (441)
Mississippi (3)
Missouri (86)
Montana (30)
Nebraska (25)
Nevada (77)
New Hampshire (70)
New Jersey (2019)
New Mexico (30)
New York (2038)
North Carolina (1115)
North Dakota (9)
Northern California (3181)
Ohio (230)
Oklahoma (15)
Oregon (38)
Pennsylvania (1568)
Puerto Rico (17)
Rhode Island (37)
South America (1111)
South Carolina (32)
South Dakota (1)
Southern California (2709)
Tennessee (120)
Texas (1081)
United States (27141)
Utah (214)
Virginia (179)
Washington D.C. (74)
Washington State (628)
West Virginia (4)
Wisconsin (66)
719,349 Results for "mirador therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
A Conversation With Mark McKenna, CEO of Mirador
In the third podcast in a special series focused on BioSpace’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Mark McKenna, CEO of Mirador Therapeutics.
March 18, 2025
·
1 min read
·
Annalee Armstrong
NextGen
Mirador Pursues All Options To Be 2030’s Greatest I&I Breakthrough
Mirador debuted last year with a massive $400 million and the goal of developing game-changing therapies for inflammatory and fibrotic diseases. The company aims to enter the clinic this year.
March 18, 2025
·
3 min read
·
Annalee Armstrong
Business
Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases
Mirador Therapeutics, Inc. (Mirador) announced its launch today.
March 21, 2024
·
3 min read
Press Releases
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
November 20, 2024
·
5 min read
Business
Mirador Therapeutics Appoints Gregg Gilbert at Chief Financial Officer
September 17, 2024
·
2 min read
Press Releases
Mirador Therapeutics Appoints Gregg Gilbert as Chief Financial Officer
September 17, 2024
·
2 min read
Business
Mirador Launches with $400M in Funding, Targets Precision Medicines
Mirador Therapeutics emerged from stealth Thursday with financing from ARCH Venture Partners and Sanofi, among others, to provide precision medicines for inflammatory and fibrotic diseases.
March 21, 2024
·
2 min read
·
Tyler Patchen
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners
June 16, 2025
·
6 min read
Press Releases
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
May 29, 2025
·
4 min read
1 of 71,935
Next
